RNA interference agent givosiran appears safe in phase I trial
1. Among patients with acute intermittent porphyria (AIP), there was no difference in the proportion of any and serious adverse ...
1. Among patients with acute intermittent porphyria (AIP), there was no difference in the proportion of any and serious adverse ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.